Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Inhibikase Therapeutics, Inc. - Common Stock (NQ:IKT)

1.500 -0.020 (-1.32%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Inhibikase Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension 
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension 
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Announces Expansion of Senior Leadership Team
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
Company to host conference call on August 15, 2024 at 8:00 a.m. ET 
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
Company expects to report trial results in 4Q24 
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET 
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial Hypertension 
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET 
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
Company to pursue eleven indications for IkT-001Pro; all previously approved for treatment with imatinib mesylate 
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
- The Company continues to progress the 201 Trial evaluating risvodetinib in untreated Parkinson’s disease - 
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Dr. Milton Werner, CEO of Inhibikase Therapeutics, Inc. is Featured in an Interview With SmallCapsDaily
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
Via AB Newswire
Topics Retirement
News headline image
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
From Inhibikase Therapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.